Potenzielle Wirkstoffe identifizieren, testen oder optimieren: PROvendis bietet attraktive Technologien aus dem pharmazeutischen Bereich zur Lizenzierung, zum Kauf oder für Entwicklungskooperationen an.

Nehmen Sie Kontakt mit uns auf! Weitere Ansprechpartner*innen finden Sie auch in jedem Technologieangebot.

Kontakt:

Dr. Jürgen Walkenhorst

jw@provendis.info
+49 208 9410568

Artificial Interferons

Interferons are a family of proteins that were originally named for their ability to interfere with viral replication and propagation. To date, it is known that interferons are also involved in combating bacterial and parasitic infections, inhibit cell division, and promote or impede the differentiation of cells.

Schutzhülle aus Hefezellen

Hefezellen fallen bei der Produktion von Bier und Bioethanol als Nebenprodukt an und sind daher günstig verfügbar.

Aptamer D3P-21

Prostate cancer is the most common cancer among men. In particular, hormone refractory prostate cancer is not curable and targeted therapies are yet not available.

OsteoProtect

There are currently 200 million people suffering from osteoporosis worldwide. Low bone mass and deteriorating bone quality lead to an increased risk of fractures, high morbidity and increased mortality.

Non-random chitosans

Chitosans are a family of functional biopolymers, typically produced by partial de-N-acetylation of chitin, one of the most abundant biopolymers in the world.

Click-Mass Spectrometry of lipids

Aberrations in fatty acid metabolism are associated with pathological states and have become a focus of current research, particularly due to the interest in metabolic overload diseases.

Protein delivery into cells by HTRA1

Precise and graded manipulation of protein levels in mammalian cells is an essential experimental tool in both basic research and clinical applications.

HTRA inhibitors

High Temperature Requirement A (HTRA) proteins are serine proteases of the S1 family (trypsin/chymotrypsin-like). HTRA1 is supposed to play a role in macular degeneration, and HTRA2 has been associated with cell death in reperfusion-ischemia.

Anti-tuberculosis drug

Tuberculosis resulting from infection with Mycobacterium tuberculosis (Mtb) is a serious global health problem accounting for 1.7 million deaths in 2016. A major reason for the high morbidity and mortality caused by Mtb is the long duration of therapy and increasing multidrug-resistance of Mtb strains.

EF-Tu-binding Re-complexed antibiotics

A series of novel Re(I)-(CO)3-N-heterocyclic carbene (NHC) complexes bearing unsubstituted benzimidazol-2-ylidene ligands as well as a variety of bisimine ligands has been prepared and comprehensively characterised.

SMECS

The generation of cardiomyocytes (CMs) from pluripotent stem cells (PSCs) holds great promise for cardiac regenerative medicine.

ET-CORMs

Carbon monoxide (CO), which is endogenously produced mainly in the course of heme degradation, was recently recognized as a powerful cytoprotective and homeostatic agent.

Novel Anti-Tuberculosis Compounds

The resurgence of tuberculosis, caused primarily by Mycobacterium tuberculosis (Mtb), and the appearance of multi‐drug and extensively drug resistant Mtb strains strengthen the need for new drugs with alternative modes of action.

TiDEC (OligoThymidine-initiated-DNA-Encoded)

The need of new drugs is high in many medical indications, for instance in oncology, and infectious diseases. However, the success rate of drug research and development has declined to unsustainable levels.

A Multifunctional Linker for CAR T-cells

Chimeric antigen receptors (CARs) have been developed for the molecular engineering of effector T-cells to be used in targeted cancer therapy. CARs consist of the antigen-binding single-chain fragment (scFv) of an antibody fused via a hinge region to a transmembrane domain (TM) and to one or more intracellular signalling co-stimulatory regions.

CEACAM1 antibodies for anti-viral therapy

Cytotoxic CD8-positive T cells constitute the crucial leukocyte subpopulation for a cellular response against viral infection.

P2Y 12-receptor antagonist

Purinergic receptors have been in the focus of drug discovery for many years. Modulation of P2 receptors in platelets is of paramount importance in regulating platelet function, and as a consequence, in controlling thrombotic diseases, which are the most common cause of morbidity and mortality in the Western world.

Induced Somatic Stem Cells

Since the pioneer work published by Takahashi & Yamanaka, the technique of reprogramming cells from a differentiated to an embryonic-like status has experienced an exploding development in regard to both techniques and applications.

Parthenolide and its derivatives for use in the treatment of axonal damage

Peripheral nerve damage is a common cause of considerable functional morbidity, and healthcare expenditure.

NHR2 inhibitors

The formation and onset of the prevalent form of acute myeloid leukemia (AML, FAB subtype M2) requires RUNX1/ETO, the product of the t(8;21) chromosomal translocation.

Cure for CLL

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries. The disease is very heterogeneous with some patients showing extremely slow progression while others proceed rapidly into advanced disease stages and require immediate treatment.

Druggable oncogenic fusions

Cancer patients frequently bear therapeutically relevant genome alteration. For instance, lung adenocarcinomas of patients that have never smoked carry genome alterations affecting kinases, such as EGFR mutations and translocations affecting ALK, ROS1 and RET genes.

ALXAN

Adenosine is a modulator of many physiological and pathophysiological processes in the central nervous system (CNS).

Exosomes

Exosomes are nano-sized, secreted cell organelles that are released by a huge variety of different cell species, including mesenchymal stem cells (MSCs). Containing a combination of lipids and proteins as well as RNAs, exosomes participate in intercellular communication processes.

CorA as anthelmintic (Human filariasis)

Human filariasis (elephantiasis and river blindness) is caused by the nematodes W. bancrofti and O. volvulus, transmitted via blood sucking insects.

Engineering approach for enzyme replacement therapy

Metachromatic leukodystrophy (MLD) is a lysosomal storage disease caused by the deficient activity of arylsulfatase A (ASA).

New Cryptophycins for ADC and SMDC

The present invention combines new synthetic ways to new Cryptophycin derivatives with alternative conjugation possibilites and pico-molar cytotoxicies, for ADC and SMDC synthesis.

Nano-BioTransporter

Cancer is one of the main causes of death worldwide. One of the newer therapeutic approaches is photodynamic therapy (PDT), a treatment that uses a photosensitizing chemical substance, a particular type of light and oxygen.

Cholinergic activity enhancer

Acetylcholine (ACh) is an essential neurotransmitter with a major function in the central and peripheral nervous system. Furthermore, ACh plays a crucial role in the autonomic nervous system stimulating preganglionic parasympathetic and sympathetic nerve fibres and postganglionic parasympathetic neurons.

Spray freeze-drying

Spray freeze-drying combines the advantageous properties of the well-established techniques spray drying and freeze-drying.

MRGPRX4 Receptor Agonists and Antagonists

G protein-coupled receptors (GPCRs) are the largest group of membrane receptor proteins and represent the most successful targets of drug therapy.

SMA therapy approach

Spinal muscular atrophy (SMA) is an autosomal recessive disorder based on the loss of the survival motor neuron 1 (SMN1) genes.

D-VLAP

Preeclampsia is a potentially life-threatening multisystem disease affecting 4% to 8% of pregnant women after the 20th week of gestation (EGA).

MRGX2 Receptor Antagonists

G protein-coupled receptors (GPCRs) are the largest group of membrane receptor proteins and represent the most successful targets of drug therapy.

Split Inteins Without Active Site Cysteine

Inteins are protein domains that auto-catalyze protein-splicing of their flanking regions with a peptide bond.

NMDAR Antagonists as new Antidiabetic Medication

According to the International Diabetes Federation (IDF), diabetes affects close to 400 million people worldwide and caused 500 billion Euros in health expenditure in 2013.